Eisai R&d Management Co., Ltd.

Eisai Company, Limited

Tohoku University

Kazutomi Kusano

Richard S Clark

Fumiyoshi Matsuura

Kazunobu Kira

Hiroshi Azuma

Shinsuke Hirota

Takao Omae

Atsushi Inoue

Tadashi Nagakura

Tatsuo Horizoe

Kimiyo Tabata

Naoto Ishii

Osamu Asano

Kazuki Miyazaki

Masanobu Shinoda

Yasutaka Takase

Takao Saeki

Manabu Shirato

So Yasui

Hisashi Wakita

Atsushi Takemura

Mai Saeki, Legal Representative

Rika Ueda

Yasushi Yamazoe

Kiyoshi Nagata

Tomoko Saeki, Legal Representative

Masaki Mikamoto

Takao (deceased) Saeki

By oral administration of a compound represented by the following Formula (I): the blood level of Compound (IV): which has an excellent inhibitory action against blood coagulation factor VIIa and the anticoagulant action, reaches a level sufficient for expression of its pharmacological actions. Therefore, the compound of the present invention is useful as a therapeutic and/or prophylactic agent for diseases caused by thrombus formation. 

Prodrug of triazolone compound

A compound represented by the following general formula (1) or salts thereof or hydrates of the foregoing: wherein R, R, Rand Reach independently represent hydrogen, etc.; Rrepresents optionally substituted phenyl, etc.; Rrepresents optionally substituted C6-10 aryl, etc.; and Zand Zeach independently represent hydrogen.

Triazolone derivatives

A compound represented by the following formula (I), salt thereof, or hydrate thereof, can effectively relieve itch caused by atopic disease or the like: wherein R represents hydroxyl, Calkoxy optionally substituted with Calkoxy, or amino optionally substituted with Calkyl.

4-(3-benzoylaminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline derivatives

A Compound represented by the following general formula (1): wherein R, R, Rand Reach independently represent hydrogen, etc.; Rrepresents optionally substituted phenyl, etc.; Rrepresents optionally substituted C6-10 aryl, etc.; and Zand Zeach independently represent hydrogen or salts thereof or hydrates of the foregoing.

A reporter vector which can evaluate the ability of a drug to induce CYP1A2 or both of CYP1A1 and CYP1A2 and a method for evaluation of the ability of a drug to induce CYP1A2 or both of CYP1A1 and CYP1A2 by using the reporter vector. A reporter system which can evaluate the ability of a drug capable of inducing CYP1A2 or both of CYP1A1 and CYP1A2 is completed by constructing a reporter vector having a reporter gene linked to the 3' end of a region between CYP1A1 and CYP1A2 or a reporter vector having different reporter genes linked to the both ends of the region, respectively, so as to sandwich the region, and a reporter vector having a deletion mutation in the region, and confirming that the expression of a reporter molecule is increased by the drug capable of inducing CYP1A2 or both of CYP1A1 and CYP1A2 in the reporter system using the reporter vector.

Reporter vector for use in evaluation of CYP1A2 induction

A Compound represented by the following general formula (1), salts thereof or hydrates of the foregoing is a novel compound useful for treatment and/or prevention of diseases associated with thrombus formation, and which is safer with suitable physicochemical stability. [wherein R, R, Rand Reach independently represent hydrogen, etc.; Rrepresents optionally substituted phenyl, etc.; Rrepresents optionally substituted C6-10 aryl, etc.; and Zand Zeach independently represent hydrogen]

Growing community of inventors

Tsukuba, Japan

Kazutomi Kusano